Ltd. "NyuVak" in cooperation with the biotech company Agenus started construction of facilities for the production of personalized cancer therapeutic vaccine Onkofag in Russia on the basis of CHT "KhimRar."
Recall, Agenus provides "NyuVaku" exclusive license to manufacture, marketing and sale of vaccines, as well as the right to conduct clinical trials in combination Onkofaga with co-adjuvant technology in the Russian Federation and CIS countries.
Onkofag received approval for use in Russia as a means of adjuvant therapy for kidney cancer patients with an average risk of recurrence of the disease in April 2008, the vaccine is obtained from each patient’s tumor cells, contains the "antigenic fingerprint" was his cancer cells and acts by reprogramming immune system, causing the attack affects only the cancer cells bearing the active print. Thus Onkofag not affect healthy tissue and thus reduces side effects resulting in a weakening of the body, and almost always arise with conventional cancer therapies, such as chemotherapy and radiotherapy.
Ltd. "NyuVak" — a subsidiary of CHT "KhimRar." In December 2010, she became one of the first residents of the innovation center "Skolkovo" in the Moscow region.